Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Discussion: Additional treatment options impact first-line treatment of mRCC

Dr Thomas Hutson; Prof Stéphan Oudard; Prof Patrick Schöffski; Dr Ignacio Durán

Discussion: Additional treatment options impact first-line treatment of mRCC ( Dr Thomas Hutson; Prof Stéphan Oudard; Prof Patrick Schöffski; Dr Ignacio Durán )

Additional treatment options impact first-line treatment of mRCC: Yes

Prof Patrick Schöffski - University Hospitals Leuven, Leuven, Belgium

Additional treatment options impact first-line treatment of mRCC: Yes ( Prof Patrick Schöffski - University Hospitals Leuven, Leuven, Belgium )

What have we learned? Expert perspectives

Dr Thomas Hutson; Prof Stéphan Oudard; Prof Patrick Schöffski; Dr Ignacio Durán

What have we learned? Expert perspectives ( Dr Thomas Hutson; Prof Stéphan Oudard; Prof Patrick Schöffski; Dr Ignacio Durán )

From clinical trial to clinical practice: Evidence from the real world

Dr Ignacio Durán - Associate Director of Clinical Research at START Madrid...

From clinical trial to clinical practice: Evidence from the real world ( Dr Ignacio Durán - Associate Director of Clinical Research at START Madrid, Madrid, Spain )

IEO to have a new Scientific Director at the end of the year when Prof Umberto...

Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy

IEO to have a new Scientific Director at the end of the year when Prof Umberto Veronesi hands over the role to Prof Roberto Orecchia ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )

The evolving treatment landscape for HER2-positive metastatic breast cancer

Dr Hatem Azim - Institut Jules Bordet, Brussels, Belgium

The evolving treatment landscape for HER2-positive metastatic breast cancer ( Dr Hatem Azim - Institut Jules Bordet, Brussels, Belgium )

Navigating current treatment options for HER2-positive MBC: Patient journey 1

Dr Rupert Bartsch - Medical University of Vienna, Vienna, Austria

Navigating current treatment options for HER2-positive MBC: Patient journey 1 ( Dr Rupert Bartsch - Medical University of Vienna, Vienna, Austria )

ecancermedicalscience editor's choice for September 2014

Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy

ecancermedicalscience editor's choice for September 2014 ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )

Benefits of investing in skin cancer prevention

Craig Sinclair - Cancer Council Victoria, Victoria, Australia

Benefits of investing in skin cancer prevention ( Craig Sinclair - Cancer Council Victoria, Victoria, Australia )

Preventing skin cancer worldwide and the impact of different regulatory and...

Prof Darrell Rigel - New York University Medical Center, New York, USA

Preventing skin cancer worldwide and the impact of different regulatory and economic priorities ( Prof Darrell Rigel - New York University Medical Center, New York, USA )

The Euro Melanoma campaign and the importance of communication, education, and...

Prof Veronique del Marmol - Chair of Euromelanoma Europe, Brussels, Belgium

The Euro Melanoma campaign and the importance of communication, education, and understanding of skin cancer ( Prof Veronique del Marmol - Chair of Euromelanoma Europe, Brussels, Belgium )

Overview of skin cancer treatments, past, present and future

Prof John Hawk - President of the World Congress on Cancers of the Skin 2014

Overview of skin cancer treatments, past, present and future ( Prof John Hawk - President of the World Congress on Cancers of the Skin 2014 )

More from ecancer